Brian Till

Title: Brian Till: Innovator in CD20 Immunotherapy

Introduction

Brian Till is a notable inventor based in Seattle, WA (US). He has made significant contributions to the field of immunotherapy, particularly in the treatment of diseases associated with CD20 expression. With a total of 2 patents, his work is paving the way for advancements in cancer treatment.

Latest Patents

Brian Till's latest patents focus on compositions and methods for CD20 immunotherapy. The present disclosure provides compositions and uses thereof for treating a disease or disorder associated with CD20 expression. Treatments of this disclosure include the use of a host cell expressing a fusion protein, such as an anti-CD20 CAR, optionally in combination with a CD20-specific binding molecule, a chemotherapeutic, an inhibitor of an immunosuppression component, or combinations thereof.

Career Highlights

Throughout his career, Brian has worked with prestigious institutions such as the Fred Hutchinson Cancer Center and the Fred Hutchinson Cancer Research Center. His experience in these organizations has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.

Collaborations

One of his notable coworkers is Oliver Press, with whom he has likely shared insights and expertise in the realm of immunotherapy.

Conclusion

Brian Till's innovative work in CD20 immunotherapy exemplifies the impact of dedicated inventors in the medical field. His patents and collaborations continue to influence the development of effective treatments for patients.